As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal ...

"Evidence suggests that nitrous oxide affects the glutamate system in the brain, which is important for how mood-related ...

Nitrous oxide may offer quick, short-term relief for people with major depression, especially those who haven’t responded to ...

Vestibular Migraine (VM) is a common clinical neurological disorder characterized by recurrent episodes of dizziness and headaches. It has a significant genetic predisposition and a high morbidity and ...

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company and HOPE ...

Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. - Designed to Help Address the Needs of Over 13 Million ...

BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay” or the 'Company”), a global leader in advanced noninvasive brain ...

DOHA: The View Hospital, in affiliation with Cedars-Sinai, offers Repetitive Transcranial Magnetic Stimulation (rTMS) therapy at its Psychiatry Department. This advanced, non-invasive treatment ...

The FDA has granted 510(k) clearance and a label expansion for a transcranial magnetic stimulation device to treat patients ...

Q3 2025 Earnings Call Transcript November 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Austin, Texas, United States, November 17th, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 ...